Compared to MFF, DNM1L exhibits relatively higher frequencies of genetic alterations in human B cell malignancies, including 7.1% (1/14) of mutations in NHL (75), 3.8% (2/53) of mutations in DLBCL (76), 0.63% (1/160) of mutations in CLL (77), 0.49% (1/205) of mutations in MM (78) and 0.24% (2/819) of amplifications in pediatric ALL (TARGET, 2018) (Supplementary Figure 8B). The gene discussed is DNM1L; the disease is non-Hodgkin lymphoma.